Facebook      Twitter




HPV-Related Diseases in HIV-Infected Individuals (18HH01)

Debra Chew, MD, MPH, Clinical Assistant Professor, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School, Lisa Dever, MD, Vice Chair for Faculty Development in the Department of Medicine, Clinical Chief of Infectious Diseases and the Director of the Infectious Disease Fellows, Rutgers New Jersey Medical School, and Shobha Swaminathan, MD, Assistant Professor, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School


Release Date: December 1, 2015
Expired: November 30, 2017
Activity Code: 18HH01

This content is being provided for informational purposes only.

If you have any questions about this process, please email the Center for Continuing and Outreach Education at ccoereg@ca.rutgers.edu or call CCOE Enrollment Services at (800) 227-4852.

As seen in the Winter 2015 edition of



Provided by François-Xavier Bagnoud Center, School of Nursing, Rutgers, The State University of New Jersey and the Center for Continuing and Outreach Education at Rutgers Biomedical and Health Sciences.


This activity is supported by an educational grant from the New Jersey Department of Health (NJDOH)— Division of HIV, STD and TB Services, through an MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.”

Statement of Need

HIV-infected individuals are at increased risk for HPV infection, persistent infection and anogenital cancers associated with HPV. In the post-HAART era, cervical cancer incidence among HIV-infected women in US has been unchanged, and anal cancer continues to increase. New treatment options are expanding for anal dysplasia and offer more hope of effective treatment. Though guidelines on routine anal cancer screening have not been established, it may be a reasonable cancer prevention strategy among those with HIV. Data on efficacy studies on prevention of HPV-associated cancers through prophylactic vaccination in HIV individuals are limited and ongoing.

This activity will assist health care providers with implementation of current recommendations for diagnosing and treating HPV infection.

Target Audience

This activity is designed for physicians, physician assistants, advanced practice nurses, nurses, dentists, health educators and other health care professionals in New Jersey who are involved in the care of people infected with HIV and their HIV non-infected partners.

Method of Participation

Participants should read the learning objectives, review the activity in its entirety, and then complete the self-assessment test, which consists of a series of multiple-choice questions. Upon completing this activity as designed and achieving a passing score of 70% or more on the self-assessment test and submitting a course evaluation, participants will receive a printable credit statement.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Describe the prevalence of HPV infection, intraepithelial neoplasia, and other HPV-associated cancers among HIV-infected individuals.
  2. Summarize national guidelines regarding routine cervical cytologic screening of HIV-infected women, and HPV vaccination use in all HIV-infected 11-26 year olds.
  3. Discuss guidelines for treatment of cervical intraepithelial neoplasia, and treatment options for the anal intra-epithelial neoplasia in HIV-infected individuals.


Activity Director/Academic Advisor

Jihad Slim, MD, Medical Director, NJDOH-Division of HIV, STD and TB Services

Planning Committee

Shobha Swaminathan, MD, Assistant Professor, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School

Connie Calisti-Myers, JD, Assistant Commissioner, NJDOH-Division of HIV, STD and TB Services

Andrea Norberg, MS, RN, Executive Director, FXB Center, Rutgers

John Nelson, PhD, CPNP, Program Director, AETC NCRC, FXB Center, Rutgers

Michelle Thompson, Program Manager, FXB Center, Rutgers

Macsu Hill, MPH, CHES, Program Coordinator, FXB Center, Rutgers

Elizabeth Ward, MSJ, Executive Director, Rutgers CCOE

Activity Authors

Debra Chew, MD, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School

Lisa Dever, MD, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School

Shobha Swaminathan, MD, Division of Infectious Diseases, Department of
Medicine, Rutgers New Jersey Medical School


Credit is no longer available for this activity.

Peer Review

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, CCOE has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by John Nelson, PhD, CPNP.

Field Test:
This activity was field tested for time required for participation by Marshall Glesby, MD, MPH, Lisa A. Pittarelli, MD, FACP, Noa’a Shimoni, MD, MPH, Laura Bogert, BSN, RN, Anna M. Haywood, MSN, RN, and Renée Powell, BS, RN.

Disclosure Disclaimer

In accordance with the disclosure policies of Rutgers University and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Disclosure Declarations

Jihad Slim, MD receives grant/research support from Gilead Sciences and ViiV Healthcare. He also is a member of the Speaker’s Bureau for AbbVie, Bristol-Myers Squibb, Janssen Pharmaceuticals and Merck & Co.

Shobha Swaminathan, MD receives grant/research support from Gilead Sciences.

All other authors, planning committee members, peer reviewers and field testers have no relevant financial relationships to disclose.

Off-Label/Investigational Usage Disclosure

This activity contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

Trichloroacetic acid, imiquimod, cidofovir, or 5-fluorouracil topical therapy for small low-grade anal intraepithelial neoplasia lesions; ifrared coagulation or electrocautery/ hyfrecation ablation therapy for high-grade or larger anal intraepithelial neoplasia lesions.

Content Disclaimer

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDOH – Division of HIV, STD and TB Services, any manufacturer of pharmaceuticals or devices, or Rutgers University. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

Copyright © 2015 Rutgers University

All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers University.

Privacy Policy

To review Rutgers' privacy policy, please see: http://ccoe.rbhs.rutgers.edu/general/privacypolicy.html

Please direct CE related or technical questions to Rutgers at 973-972-4267 or email ccoe@ca.rutgers.edu.


© Copyright 2020, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy